Allergen immunotherapy and biologics in respiratory allergy: friends or foes?. Issue 1 (February 2021)

• Record Type: Journal Article
• Authors: Malipiero, Giacomo; Melone, Giulio; Puggioni, Francesca; Pawankar, Ruby; Heffler, Enrico; Paoletti, Giovanni
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 21:Issue 1(2021)
• Publication Date: 2021-02
• Subjects: allergen immunotherapy -- asthma -- biologicals -- immune checkpoints -- respiratory allergy -- tolerance; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000707
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: Allergen-specific immunotherapy has established as an indispensable disease-modifying treatment in allergy practice but its safety and efficacy might be furtherly improved by combining it with other drugs or therapeutic intervention that co-modulate immune type 2 immune networks Recent findings: In the past two decades, clinical research focused on AIT and omalizumab co-treatment to improve both safety and long-term efficacy of allergic disease treatment. Recently, combination of AIT with other biologicals targeting different mediators of type 2 inflammation has been set up with interesting preliminary results. Moreover, AIT current contraindication might be overcome by contemporarily controlling underlying type 2 inflammation in severe atopic patients. Summary: AIT--biological combination treatment can realize a complex multitargeted treatment strategy allowing for consistently improving disease control and sparing steroid administration.